EZH2 and epithelioid sarcoma: Tazemetostat (EPZ6438, 50,Figure 7(D)) is a first-in-class and the only one so far KMT-targeted epigenetic regulator with the FDA approval for patients with metastatic or locally advanced epithelioid sarcoma and follicular lymphoma that inhibits enhancer of zeste homolog 2 (EZH2) with high potency65,.66